LDLR and type 2 diabetes mellitus: In apolipoprotein E-deficient (ApoE−/−) mice with T2DM induced with streptozotocin (STZ), dapagliflozin treatment can attenuate atherosclerosis lesions and decrease atherosclerotic macrophage infiltration [170,171], an effect also observed in ApoE−/− mice fed with a high-fat diet [172], in a normoglycemic rabbit model of atherosclerosis [173], in LDL-receptor-deficient (Ldlr−/−) mice with a high-fat and high-sucrose diabetogenic diet [174], or in T2DM rats [175].